Cannabis and Migraine: Promising, With a Rebound Trap

Migraine is a neurological disorder, not a bad headache. Attacks involve trigeminovascular activation, CGRP release, cortical spreading depression and central sensitisation, which is why it responds to specific drugs and not simply to painkillers.

Cannabis has a real mechanistic connection to that biology, encouraging low-quality evidence, and one specific risk that most enthusiastic coverage leaves out.

Why the Mechanism Is Plausible

The endocannabinoid system modulates pain processing in the trigeminal system, the pathway central to migraine. Anandamide has been shown to affect trigeminovascular signalling, and CB1 receptors are present in the periaqueductal grey and trigeminal nucleus, both involved in migraine.

This underpins the clinical endocannabinoid deficiency hypothesis, which proposes that reduced endocannabinoid tone contributes to migraine, fibromyalgia and irritable bowel syndrome. Some studies have reported lower anandamide levels in the cerebrospinal fluid of chronic migraine patients.

The hypothesis is interesting and not established. Treat it as a reasonable framework rather than a demonstrated cause.

What the Human Evidence Shows

The evidence is mostly observational, retrospective or from small trials, which limits confidence.

Retrospective and survey data consistently report reduced migraine frequency among patients using cannabis, with many reporting fewer headache days per month. Self-selection and expectation effects are obvious limitations.

Acute attacks. Some research using archival app-based symptom tracking has reported reductions in headache severity after inhaled cannabis use, with tolerance appearing over time.

Nabilone. A small trial in medication overuse headache reported nabilone performing comparably to or better than ibuprofen for pain and quality of life.

The overall picture is a consistent direction with weak methodology. That is a reason to consider it, not a reason to promise anything.

The Rebound Problem

This is the part that deserves more prominence than it usually gets.

Medication overuse headache is a well-established phenomenon in which frequent use of any acute headache treatment produces more frequent headaches. It happens with triptans, combination analgesics, opioids and NSAIDs, generally with use on more than about ten to fifteen days per month depending on the drug.

Cannabis is not exempt. Frequent use for acute attacks can contribute to medication overuse headache, and cannabis withdrawal itself causes headache, which closes a self-sustaining loop: headache leads to cannabis, cannabis wearing off leads to headache.

Patients frequently arrive convinced cannabis is the only thing controlling their migraines when the pattern is partly cannabis maintaining them. The way to tell is a supervised break, which is unpleasant and diagnostic.

Practical implication: if you use cannabis for acute attacks, track days per month and keep it below the threshold that applies to other acute treatments. Daily use for migraine is the specific pattern to avoid.

Prevention Versus Abortion

Migraine treatment splits into preventive and acute, and cannabis is often discussed as though it did both.

Acute use is where reports are more encouraging, with inhalation offering fast onset that suits an attack.

Preventive use would mean daily dosing, which is exactly the pattern that risks medication overuse headache and dependence. Established preventives including CGRP monoclonal antibodies, topiramate, propranolol and amitriptyline have far better evidence.

Using cannabis acutely while a proper preventive does the daily work is a more defensible structure than using cannabis daily.

Product Considerations

Inhalation suits acute attacks because of rapid onset. Nausea and vomiting during attacks can make oral dosing unreliable anyway.

Low doses. High-THC products can worsen nausea and anxiety, both common in migraine.

Balanced or CBD-containing products may be better tolerated, though evidence for CBD alone in migraine is thin.

Photophobia and sensory sensitivity are part of attacks, and smoking in a bright environment is its own problem.

Who Should Be Cautious

Anyone with migraine with aura should know that aura is associated with slightly elevated stroke risk, and cannabis acutely raises heart rate. This is worth a neurologist conversation rather than alarm.

People with frequent attacks, since higher frequency means more temptation toward daily use.

Those already on multiple acute medications, where overuse risk compounds.

Bottom Line

The endocannabinoid link to trigeminal pain processing is real, and observational data on reduced migraine frequency is consistent but weak. The distinctive risk is medication overuse headache, which cannabis can cause exactly as triptans and analgesics do, with withdrawal headache reinforcing the cycle. Use it for attacks, keep the monthly count down, and let an established preventive do the daily work.

Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before making any health-related decisions.